2023 Alzheimer’s Disease Public Education Forum
Chairs: Ranjan Duara, MD, FAAN, Mount Sinai Medical Center, Miami Beach
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine
The FDA has provided accelerated approvals for the first time for two disease-modifying drugs for Alzheimer’s disease.
These two drugs, and one additional drug which is expected to receive accelerated approval
in 2023, are monoclonal antibody treatments, designed to remove the toxic beta amyloid protein, associated with Alzheimer’s disease, from the brain.
In this Public Information Forum our goal is to provide information and answer questions about this new class of drugs for Alzheimer’s disease, from six experts in the field.
Sunday, April 2, 2023 1:30 pm – 4:20 pm US Eastern Time
FREE REGISTRATION – Program details and online registration at mcisymposium.org/forum